Skip to Content

Alcon Wraps Deal For Sirion Drug Rights

From Associated Press (March 30, 2010)

NEW YORK -- Eye care products maker Alcon Inc. said Tuesday that it completed its acquisition of the rights to two eye drugs from Sirion Therapeutics.

The Swiss company said it is gaining the U.S. rights to Durezol, which is approved as a treatment for inflammation and pain after eye surgery. It also gained the rights to market the immune suppressant drug candidate Zyclorin in all countries outside of Latin America.

Alcon did not disclose terms of the deal. The company said it is also considering an option to buy Zirgan, an antiviral drug approval to treat corneal ulcers.

Alcon stock rose 14 cents to $160.60 in midday trading.


Posted: March 2010